Grifols, S.A. (NASDAQ:GRFS) shares were up 5.3% during mid-day trading on Tuesday . The company traded as high as $23.69 and last traded at $23.65. Approximately 1,049,198 shares were traded during mid-day trading, an increase of 74% from the average daily volume of 601,437 shares. The stock had previously closed at $22.45.
Several analysts have recently weighed in on GRFS shares. Zacks Investment Research upgraded shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, July 4th. Bank of America Corp restated a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. Citigroup Inc. started coverage on shares of Grifols, in a research report on Tuesday. They set a “buy” rating for the company. Finally, BidaskClub downgraded shares of Grifols, from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $24.00.
The company has a market capitalization of $32.32 billion, a price-to-earnings ratio of 49.68 and a beta of 0.98. The firm has a 50 day moving average of $21.40 and a 200 day moving average of $21.06.
Several hedge funds have recently added to or reduced their stakes in GRFS. Advisory Services Network LLC grew its position in shares of Grifols, by 26.2% during the second quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after buying an additional 1,987 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Grifols, during the second quarter worth approximately $223,000. Stifel Financial Corp grew its position in shares of Grifols, by 4.3% during the first quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after buying an additional 476 shares in the last quarter. Stevens Capital Management LP acquired a new stake in shares of Grifols, during the second quarter worth approximately $236,000. Finally, Advisor Group Inc. grew its position in shares of Grifols, by 2.8% during the second quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after buying an additional 309 shares in the last quarter. 21.93% of the stock is owned by institutional investors and hedge funds.
Grifols, Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.